Investigating effect of chamomile hydroalcoholic extract on movement disorders in the animal model of Parkinson's disease
محورهای موضوعی : مجله گیاهان داروییشهربانو عالمی رستمی 1 , مریم رفیعی راد 2
1 - Department of Biology,Islamic Azad Univercity,Gomishan center , Gorgan Branch,Gorgan Iran
2 - Department of Biology, faculty of Sciences, Islamic Azad University, Izeh branch, Izeh-Iran
کلید واژه: Rats, Movement disorder, Chamomile extract, Parkinson's disease (PD),
چکیده مقاله :
Background & Aim:Parkinson's disease (PD) is a kind of disorder in the nervous system, which is characterized with multiple movement disorders. Factors such as oxidative stress are the most important causes for the degeneration of dopaminergic neurons in the substantia nigra and occurrence of Parkinson's disease. Thus, medications that have antioxidant functions could be an interesting target for treating the movement disorders caused by Parkinson's disease. Chamomile is the natural source of antioxidants. Experimental: In this study, 50 adult male Wistar rats were randomly divided into control and Parkinson's groups with 10 rats along with 3 Parkinson's groups, which received chamomile extract by gastric gavage method and doses of 5, 10, and 50 mg/kg once per day for 14 days. Also, 8 μg of 6-hydroxydopamine (6-OHDA) neurotoxin in 2 μl saline containing 1% ascorbic acid was injected into medial forebrain bundle (MFB) of the left hemisphere of the brain of the rats to induce Parkinson's disease. Results were presented as mean ± SD, one-way analysis of variance, and Tukey's post-hoc test. Results:Following subcutaneous injection 2.5 mg/kg apomorphine 14 days after injury with 6-OHDA in MFB of left brain, animals were rotated 360 degrees to the right by 10 Recommended applications/industries: Probably because of its strong antioxidant effect and interference with the activity of movement pathway receptors, chamomile extract can be used to improve and reduce the movement disorders of Parkinson's disease in addition to pharmacotherapy.
مینه وهدف: بیماری پارکینسون نوعی تحلیل در سیستم عصبی است که با اختلالات حرکتی متعددی شناخته می‌شود. عواملی از قبیل استرس اکسیداتیو از مهم‌ترین علل دژنراسیون نورون‌های دوپامینرژیکی جسم سیاه و ایجاد پارکینسون به شمار می روند. بنابراین داروهایی که دارای عمل آنت ی اکسیدانی م ی باشند، می توانند ب ه عنوان هدف جالب توجهی برای درمان اختلالات حرکتی پارکینسون باشند . بابونه منبع طبیعی آنتی اکسیدان است. مواد و روش ها: در این مطالعه از 50 سر موش صحرایی نر بالغ استفاده‌گردید که به‌طور تصادفی به گروه‌های 10تایی کنترل، پارکینسونی، و سه گروه پارکینسونی که روزانه یک‌بار به مدت 14روز به ترتیب دوزهای mg/kg10،25و 50 عصاره گل بابونه را به روش گاواژ دریافت نمودند، تقسیم شدند. بیماری پارکینسون با تزریق 8میکروگرم سم عصبی 6_هیدروکسی دوپامین (6-OHDA) در 2میکرولیتر سالین دارای 1% اسید اسکوربیک درون دسته میانی_قدامی (MFB)نیمکره چپ مغز موش‌ها القاء شد. نتایج به صورت میانگین و انحراف از معیار( mean± SEM)، آنالیز و واریانس یک طرفه و تست پشتیبان TUKEY ارائه شدند. یافته ها: ضایعه در MFB سمت چپ مغز با 6-OHDA موجب‌گردید تا 14 روز بعد از ضایعه حیوانات متعاقب تجویز زیرجلدی mg/kg 5/2 آپومورفین در جهت راست به میزان 10< دور در دقیقه چرخش 360 درجه داشته باشند و نیز در تست‌های حرکتی (حفظ تعادل، بی‌حرکتی و طول قدم) نسبت به گروه کنترل اختلاف معنی‌داری را نشان دادند. درمان حیوانات پارکینسونی با دوزهای مختلف عصاره گل بابونه در مقایسه با گروه پارکینسونی بدون درمان، موجب بهبودی معنی‌دار فعالیت‌های حرکتی گردید و دوز mg/kg10 و 50 بیشترین اثرات درمانی را نشان دادند. توصیه های کاربردی/صنعتی: عصاره گل بابونه احتمالا ًبه‌دلیل خاصیت آنتی‌اکسیدانی قوی و تداخل با فعالیت گیرنده‌های مسیرهای حرکتی می‌تواند جهت بهبود و کاهش اختلالات حرکتی پارکینسون مورد استفاده قرار گیرد.
Amsterdam J.D., Li Y., Soeller I., Rockwell K., Mao J.J. and Shults J. 2009. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita chamomile. extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacol 29, 378-82.
Berghauzen-Maciejewska K., Wardas J., Kosmowska B., Domin H., Smialowska M., Glowacka U. and Ossowska K. 2016. Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment. Neuroscience 314, 22-34.
Blanchet J., Longpre F., Bureau G., Morissette M., DiPaolo T., Bronchti G. and Martinoli M.G. 2008. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1243-50.
Braak H., Rub U., Schultz C. and Del Tredici K. 2006. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. Journal of Alzheimers Dis 9, 35-44.
Bub A., Watzl B., Blockhaus M., Briviba K., Liegibel U., Muller H., Pool-Zobel B.L. and Rechkemmer G. 2003. Fruit juice consumption modulates antioxidative status, immune status and DNA damage.The Journal of Nutritional Biochemistry
14, 90-8.
Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S and RN T. 2002. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cellular and molecular neurobiology 22, 227-37.
Dekundy A., Pietraszek M., Schaefer D., Cenci M.A. and Danysz W. 2006. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Research Bull 69, 318-26.
Ebadi M., Srinivasan S.K. and Baxi M.D. 1996. Oxidative stress and antioxidant therapy in Parkinson's disease. Progress Neurobiol 48, 1-19.
Ebrahimi A. and Schluesener H. 2012. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Ageing Research Reviwe 11, 329-45.
Gajcy K., Lochynski S. and Librowski T. 2010. A role of GABA analogues in the treatment of neurological diseases. Current Medicinal Chemistry
17, 2338-47.
gholami Z and M a. 2014. Antinociceptive effects of matricaria chamomilla L. ethanolic extract in mice. journal of ilam university of medical sciences 21, 312-7.
Golparvar AR, A G.P. and M. K. 2011. Determination of the effective traits on essence percent and dry flower yield in German chamomile Matricaria chamomilla L.. populations. Journal of Medicinal Plant Research
5, 3242 - 6.
Jankovic J. 2008. Parkinson's disease: clinical features and diagnosis. Journal Neurol Neurosurg Psychiatry 79, 368-76.
Javier G.A , Gaspar R , Luisa V.G.M and P. J. 2006. Acute intake of phenolic-rich juice improves antioxidant status in healthy subjects. Nutrition research. 27, 330-9.
Kahnberg P., Lager E., Rosenberg C., Schougaard J., Camet L., Sterner O., Ostergaard Nielsen E., Nielsen M. and Liljefors T. 2002. Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABAA. receptor.Journal of Medicinal Chemistry, 45, 4188-201.
Kleppner S.R. and Tobin A.J. 2001. GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Expert Opin Ther Targets 5, 219-39.
Li R., Peng N., Du F., Li X.P. and Le W.D. 2006. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao 26, 376-80.
Marder M and P A. 2002. GABAA-receptor ligands of flavonoid structure. Current Topics in Medicinal Chemistry, 2, 853-67.
McKay D.L. and Blumberg J.B. 2006. A review of the bioactivity and potential health benefits of chamomile tea Matricaria recutita L. Phytother Research 20, 519-30.
Motevalizadekakhky A. 2012. Antimicrobial activity and chemical composition of essential oils of chamomile from Neyshabur, Iran. Journal Medical Plants Research 6, 820-4.
Abou-Sleiman P.M., Muqit M.M. and Wood N.W. 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease.Nature Reviews Neuroscience7, 207-19.
Orallo F., Alvarez E., Camina M., Leiro J.M., Gomez E. and Fernandez P. 2002. The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Molecular Pharmacology, 61, 294-302.
Philippens I.H., t Hart B.A. and Torres G. 2010. The MPTP marmoset model of parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseases. Drug Discovery Today 15, 985-90.
Rice-Evans C.A., Miller N.J. and Paganga G. 1996. Structure-antioxidant activity relationships of flavonoids and phenolic acids.Free Radical Biology and Medicine, 20, 933-56.
Rosenthal A. 1998. Specification and survival of dopaminergic neurons in the mammalian midbrain. Advance Pharmacol, 42, 908-11.
Sarkaki A, Norooz Zare F, Farbood Y and P A.A. 2013. Impaired movements in 6-OHDA induced Parkinson’s rat model improves by pomegranate seed hydroalcoholic extract. HealthMED journal 7, 348-58.
Sarkaki A., Eidypour Z., Motamedi F., Keramati K. and Farbood Y. 2012. Motor disturbances and thalamic electrical power of frequency bands' improve by grape seed extract in animal model of Parkinson's disease. Avicenna Journal Phytomedicin, 2, 222-32.
Sarris J., Panossian A., Schweitzer I., Stough C. and Scholey A. 2011. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. European Neuropsychopharmacol, 21, 841-60.
Seifi Zangeneh M, Rafieirad M and H. S. 2015. The effect of Kardeh Biarum Bovei. Hydro-alcoholic extract on pain threshold in STZ induced diabetic rats Journal of Herbal Drugs, 6, 137-42.
Shrivastava P., Vaibhav K., Tabassum R., Khan A., Ishrat T., Khan M.M., Ahmad A., Islam F., Safhi M.M. and Islam F. 2013. Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model. The Journal of Nutritional Biochemistry 24, 680-7.
Singh O., Khanam Z., Misra N. and Srivastava M.K. 2011. Chamomile Matricaria chamomilla L. An overview. Pharmacogn Review, 5, 82-95.
Srivastava J.K., Shankar E. and Gupta S. 2010. Chamomile: A herbal medicine of the past with bright future. Molecular Medicine Reports. 3, 895-901.
Sultan Ahmad, M and Yadav, R. 2012. Evaluation of Antigenotoxic Potential of Ellagic Acid against Aflatoxin B1-Induced Genotoxicity. Indian Journal of Fundamental and Applied Life Sciences 2, 177-84.
Sun W., Sugiyama K., Fang X., Yamaguchi H., Akamine S., Magata Y. and Namba H. 2010. Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats. Brain Research 1317, 227-35.
Tanaka K., Ogawa N. and Asanuma M. 2006. Molecular basis of 6-hydroxydopamine-induced caspase activations due to increases in oxidative stress in the mouse striatum. Neuroscince Letters 410, 85-9.
Tarawneh R. and Galvin J.E. 2010. Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clinical Geriatr Med icin 26, 125-47.
Yeh C.T., Ching L.C. and Yen G.C. 2009. Inducing gene expression of cardiac antioxidant enzymes by dietary phenolic acids in rats. The Journal of Nutritional Biochemistry 20, 163-71.
Zick SM, Wright BD, Sen A and JT. A. 2011. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study.BMC Complementary and Alternative Medicine Journal 11: 78.
